Aprea Therapeutics, Inc.
For the period ended Jun 5, 2025. Filed Apr 22, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 5, 2025 · Filed Apr 22, 2025
Contents
PAY VERSUS PERFORMANCE
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between compensation actually paid to our Named Executive Officers (NEOs) and certain financial performance metrics of the Company using a methodology that has been prescribed by the SEC.
| · · · · · · · · · · · · · · | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fiscal Year · SummaryCompensationTable Totalfor PEO (1)$ · CompensationActuallyPaid to PEO$ · Average SummaryCompensationTable Total fornon-PEO NEOs (1)$ · AverageCompensationActually Paid tonon- PEO NEOs (2)$ · Value of InitialFixed$100 InvestmentBased OnTotal ShareholderReturn$ · Net Loss($ thousands) | |||||||||||
| 2024 | | 760,091 | 643,106 | 492,193 | 378,219 | | $49.70 | | (12,959) | | |
| 2023 | | 877,430 | 847,567 | 654,192 | | 547,739 | | $71.00 | | (14,287) | |
| (1) | Dr. Gilad served as our principal executive officer (“PEO”) for 2023 and 2024. Our non-PEO named executive officers (“NEO”) included Mr. Hamill and Dr. Mirza for 2024 and Mr. Hamill and Scott Coiante for 2023. Mr. Coiante ceased serving as our Senior Vice President, Chief Financial Officer and Secretary on January 30, 2023, but remained employed with us through March 31, 2023, to ensure a smooth transition of his duties and responsibilities. |
| (2) | The following amounts were deducted from / added to Summary Compensation Table (“SCT”) total compensation in accordance with the SEC-mandated adjustments to calculate Compensation Actually Paid (“CAP”) to our PEO and average CAP to our non-PEO NEOs. The fair value of equity awards was determined using methodologies and assumptions developed in a manner substantively consistent with those used to determine the grant date fair value of such awards. |
PEO SCT Total to CAP Reconciliation
| · · · · · · · | |||||
|---|---|---|---|---|---|
| Fiscal Year · 2023 · 2024 | |||||
| SCT Total | | $877,430 | | $760,091 | |
| - Grant Date Fair Value of Equity Awards Granted in Fiscal Year | | $(80,480) | | $(184,601) | |
| + Fair Value at Fiscal Year-End of Outstanding Unvested Equity Awards Granted in Fiscal Year | | $76,400 | | $83,726 | |
| ± Change in Fair Value of Outstanding Unvested Equity Awards Granted in Prior Fiscal Years | | $(13,062) | | $(23,273) | |
| + Fair Value at Vesting of Equity Awards Granted in Fiscal Year That Vested During Fiscal Year | | $— | | $— | |
| ± Change in Fair Value as of Vesting Date of Equity Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | | $(12,721) | | $7,163 | |
| - Fair Value as of Prior Fiscal Year-End of Equity Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | | $— | | $— | |
| + Dividends or Other Earnings Paid on Equity Awards in the Fiscal Year Prior to the Vesting Date that are not otherwise included in the Total Compensation for the Fiscal Year | | $— | | $— | |
| Compensation Actually Paid | | $847,567 | | $643,106 | |
| 42 | |
Non-PEO NEO Average SCT Total to Average CAP Reconciliation
| · · · · · · · | |||||
|---|---|---|---|---|---|
| Fiscal Year · 2023 · 2024 | |||||
| Average SCT Total | | $654,192 | | $492,193 | |
| - Grant Date Fair Value of Equity Awards Granted in Fiscal Year | | $(165,563) | | $(116,479) | |
| + Fair Value at Fiscal Year-End of Outstanding Unvested Equity Awards Granted in Fiscal Year | | $79,341 | | $20,947 | |
| ± Change in Fair Value of Outstanding Unvested Equity Awards Granted in Prior Fiscal Years | | $— | | $(16,884) | |
| + Fair Value at Vesting of Equity Awards Granted in Fiscal Year That Vested During Fiscal Year | | $— | | $— | |
| ± Change in Fair Value as of Vesting Date of Equity Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | | $— | | $866 | |
| - Fair Value as of Prior Fiscal Year-End of Equity Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | | $(20,231) | | $(2,424) | |
| + Dividends or Other Earnings Paid on Equity Awards in the Fiscal Year Prior to the Vesting Date that are not otherwise included in the Total Compensation for the Fiscal Year | | $— | | $— | |
| Average Compensation Actually Paid | | $547,739 | | $378,219 | |
Charts of Cap Versus Performance Metrics
The chart below illustrates the relationship between the PEO and average Non-PEO CAP amounts and the Company’s TSR during the period 2023-2024.
| | |
|---|---|
| | 43 |
The chart below illustrates the relationship between the PEO and Non-PEO CAP amounts and the Company’s Net Income during the period 2023-2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.